Wang et al. showed that high expression of C1R, chemokine (C-C-motif) ligand 2 (CCL2), and TNF receptor superfamily 1A (TNFRSF1A) in the COVID-19 pathway was significantly associated with low survival in GBM patients and immune cell infiltration, which may be used as molecular biomarkers of prognosis and immune infiltration in patients with GBM in the future [15]. The gene discussed is CCL2; the disease is glioblastoma.